ArticleAmerican journal of cancer research2026
TREM2 inhibits cholangiocarcinoma progression by regulating the TGF-β/Smad2/3 signaling pathway.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor involved in the initiation and progression of multiple cancers through various pathways. However, its role in cholangiocarcinoma (CCA) remains unclear. This study aimed to elucidate the expression characteristics and functions of TREM2 in cholangiocarcinoma (CCA). First, we assessed TREM2 expression in a retrospective cohort of 55 patients with CCA using immunohistochemistry (IHC) and confirmed its localization by double immunofluorescence staining. Second, functional assays were performed to evaluate effects of TREM2 on CCA cell proliferation, migration, and invasion. Finally, mechanistic studies focused on the TGF-β/Smad2/3 pathway and epithelial-mesenchymal transition (EMT), including drug-induced activation of the TGF-β signaling pathway. In vitro assessments evaluated gemcitabine sensitivity and apoptosis, while tumorigenicity was examined using a nude mouse xenograft model. The results demonstrated that TREM2 expression in both the tumor stroma and tumor cells was inversely correlated with clinicopathological aggressiveness: high TREM2 expression was associated with a lower T stage (P = 0.004) and a lower TNM stage (P = 0.026), whereas low TREM2 expression was an independent risk factor for poorer disease-free survival. Functional studies demonstrated that TREM2 overexpression inhibited cholangiocarcinoma cell proliferation, migration, and invasion, whereas TREM2 knockdown promoted these malignant phenotypes. Mechanistic investigations revealed that TREM2 reverses the expression of epithelial-mesenchymal transition (EMT) markers by inhibiting Smad2/3 phosphorylation, and these effects can be reversed by activators of the TGF-β signaling pathway. Additionally, TREM2 enhanced gemcitabine sensitivity by lowering the gemcitabine IC50 and promoting gemcitabine-induced apoptosis. Collectively, TREM2 exerts tumor-suppressive functions in cholangiocarcinoma and enhances chemotherapy sensitivity, suggesting its potential as a therapeutic target and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.